Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Oncopeptides in connection with entering into renewed agreements regarding a loan facility of up to EUR 30 million from the European Investment Bank
Mandate

Vinge has advised Oncopeptides in connection with entering into renewed agreements regarding a loan facility of up to EUR 30 million from the European Investment Bank

December 01, 2022 Banking and Finance Capital Markets and Public M&A Life Sciences & Health

The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.

Oncopeptides is a biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company´s lead product is approved on several markets for treatment of adult patients with multiple myeloma. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Louise Brorsson Salomon, Arvid Weimers and Kamyar Najmi (finance) as well as Dain Hård Nevonen and Linnéa Sellström (capital markets).

Related

Vinge has advised Main Capital and Pointsharp in connection with the acquisition of Meaplus AB and Nubibus Software AB

 Vinge has advised Main Capital and its portfolio company Pointsharp in connection with Pointsharp's acquisition of Meaplus AB and Nubibus Software AB. Pointsharp is a Swedish provider of identity and access management solutions as well as secure information exchange, with operations in the Nordics, DACH and Benelux. The acquisition complements Pointsharp's existing offering with capabilities in secure digital communication and strengthens the company's position in the Swedish public-sector market, particularly in the municipal and healthcare segments. The transaction is Pointsharp's sixth add-on acquisition since Main Capital became an investment partner in November 2020.
October 01, 2026

Vinge has advised Main Capital Partners on the acquisition of Confirma Software

 Confirma Software (“Confirma”) is a Nordic vertical software group providing mission-critical B2B software to SMEs in Sweden, Finland, Norway and Denmark. The company operates across five complementary software areas: ERP, Payment Solutions, Financial Solutions, Quality Management Systems and Business Process Solutions. Confirma was founded in 2019 and is headquartered in Stockholm. Supported by approximately 540 professionals, the company serves more than 25,000 customers, including over 500 municipalities, across the Nordics. By combining deep local domain expertise with software embedded in customers’ day-to-day operations, Confirma has developed long-standing customer relationships and a highly recurring revenue profile.
September 25, 2026

Vinge has advised Embracer Group in connection with a SEK 2 billion multicurrency revolving credit facility agreement entered into with SEB, DNB, Nordea and Swedbank

 Vinge has advised Embracer Group AB (publ) (“Embracer”) in connection with the entry into of a SEK 2,000,000,000 financing agreement with SEB, DNB, Nordea and Swedbank. Embracer is a global group of entrepreneurial businesses in the gaming and entertainment industry.
September 25, 2026